SuperworthLigand Pharmaceuticals EPS LGND
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $9.40
- Latest quarter, Q2 FY26
- $2.22
- +825% on a year earlier
- Fiscal year 2025
- $5.88
Ligand Pharmaceuticals' earnings per share was $9.40 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $2.22, up 825% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $5.88 | n/a |
| FY2024 | −$0.16 | −106% |
| FY2023 | $2.90 | n/a |
| FY2022 | −$1.98 | −160% |
| FY2021 | $3.32 | n/a |
| FY2020 | −$0.21 | −101% |
| FY2019 | $29.34 | +424% |
| FY2018 | $5.60 | +998% |
| FY2017 | $0.51 | +155% |
| FY2016 | $0.20 | −98% |
| FY2015 | $10.72 | +1781% |
| FY2014 | $0.57 | +4% |
| FY2013 | $0.55 | n/a |
| FY2012 | −$0.03 | −106% |
| FY2011 | $0.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.22 | +825% | $9.40 | |
| Q1 FY26 | −$0.67 | n/a | $7.42 | |
| Q4 FY25 | $2.17 | n/a | $5.88 | |
| Q3 FY25 | $5.68 | n/a | $2.07 | |
| Q2 FY25 | $0.24 | n/a | −$4.00 | |
| Q1 FY25 | −$2.21 | −147% | −$7.12 | |
| Q4 FY24 | −$1.64 | −259% | −$0.16 | |
| Q3 FY24 | −$0.39 | n/a | $2.51 | |
| Q2 FY24 | −$2.88 | −2315% | $2.31 | |
| Q1 FY24 | $4.75 | +104% | $5.32 | |
| Q4 FY23 | $1.03 | n/a | $2.90 | |
| Q3 FY23 | −$0.59 | −3050% | $0.83 |
Against its peers
Companies in Drug Manufacturers - General nearest Ligand Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| LQDALiquidia | $1.39 | |
| OGNOrganon | $0.77 | −71% a year |
| Peer median | $0.87 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Ligand Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.